A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer

被引:9
|
作者
Poel, Dennis [1 ,2 ]
Gootjes, Elske C. [1 ,2 ]
Bakkerus, Lotte [1 ,2 ]
Trypsteen, Wim [3 ,4 ]
Dekker, Henk [1 ]
van der Vliet, Hans J. [1 ]
van Grieken, Nicole C. T. [5 ]
Verhoef, Cornelis [6 ]
Buffart, Tineke E. [1 ,7 ]
Verheul, Henk M. W. [1 ,2 ]
机构
[1] VU Univ Med Ctr Amsterdam, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands
[3] Univ Ghent, Fac Med & Hlth Sci, HIV Cure Res Ctr, Dept Internal Med & Pediat, Ghent, Belgium
[4] Ghent Univ Hosp, Ghent, Belgium
[5] VU Univ Med Ctr Amsterdam, Canc Ctr Amsterdam, Dept Pathol, Amsterdam UMC, Amsterdam, Netherlands
[6] Erasmus MC Canc Inst, Div Surg Oncol, Dept Surg, Rotterdam, Netherlands
[7] Dept Gastrointestinal Oncol, Amsterdam, Netherlands
来源
CANCER MEDICINE | 2020年 / 9卷 / 20期
关键词
chemotherapy; colorectal cancer; metastases; miRNA; response prediction; serum; FOLFIRI PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; CIRCULATING MICRORNAS; FRESH-FROZEN; OPEN-LABEL; EXPRESSION; FLUOROURACIL; CHEMOTHERAPY; COMBINATION; LEUCOVORIN;
D O I
10.1002/cam4.3371
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Palliative systemic therapy is currently standard of care for patients with extensive metastatic colorectal cancer (mCRC). A biomarker predicting chemotherapy benefit which prevents toxicity from ineffective treatment is urgently needed. Therefore, a previously developed tissue-derived microRNA profile to predict clinical benefit from chemotherapy was evaluated in tissue biopsies and serum from patients with mCRC. Methods Samples were prospectively collected from patients (N = 132) who were treated with capecitabine or 5-FU/LV with oxaliplatin +/- bevacizumab. Response evaluation was performed according to RECIST 1.1 after three or four cycles, respectively. Baseline tissue and serum miRNAs expression levels of miR-17-5p, miR-20a-5p, miR-30a-5p, miR-92a-3p, miR-92b-3p, and miR-98-5p were quantified with RT-qPCR and droplet digital PCR, respectively. Combined predictive performance of selected variables was tested using logistic regression analysis. Results From 132 patients, 81 fresh frozen tissue biopsies from metastases and 93 serum samples were available. Based on expression levels of miRNAs in tissue, progressive disease could be predicted with an AUC of 0.85 (95% CI:0.72-0.91) and response could be predicted with an AUC of 0.70 (95% CI:0.56-0.80). This did not outperform clinical parameters alone (respectivelyP = .14 andP = .27). Expression levels of miR-92a-3p and miR-98-5p in serum significantly improved the predictive value of clinical parameters for response to chemotherapy (AUC 0.74, 95% CI:0.64-0.84,P = .003) in this cohort. Conclusions The additive predictive value to clinical parameters of the tissue-derived six miRNA profile for clinical benefit could not be validated in patients with mCRC treated with first-line systemic therapy. Although miR-92a-3p and miR-98-5p serum levels improved the predictive value of clinical parameters, it remained insufficient for clinical decision-making.
引用
收藏
页码:7558 / 7571
页数:14
相关论文
共 50 条
  • [1] Personalized systemic treatment of metastatic colorectal cancer
    Hofheinz, R-D
    Stintzing, S.
    INTERNIST, 2020, 61 (07): : 699 - 710
  • [2] Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: A meta-analysis
    Chen, Cui
    Sun, Peng
    Ye, Sheng
    Weng, Hui-wen
    Dai, Qiang-sheng
    JOURNAL OF BUON, 2014, 19 (04): : 917 - 924
  • [3] Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer
    Estevez-Garcia, Purificacion
    Rivera, Fernando
    Molina-Pinelo, Sonia
    Benavent, Marta
    Gomez, Javier
    Luisa Limon, Maria
    Dolores Pastor, Maria
    Martinez-Perez, Julia
    Paz-Ares, Luis
    Carnero, Amancio
    Garcia-Carbonero, Rocio
    ONCOTARGET, 2015, 6 (08) : 6151 - 6159
  • [4] Systemic treatment and primary tumor location in patients with metastatic colorectal cancer
    Antoniou, Efstathios
    Andreatos, Nikolaos
    Margonis, Georgios A.
    Papalois, Apostolos
    Wang, Jaeyun
    Damaskos, Christos
    Garmpis, Nikolaos
    Buettner, Stefan
    Deshwar, Amar
    Pappas, Vasilios
    Weiss, Matthew J.
    Pawlik, Timothy M.
    Pikoulis, Emmanouel
    JOURNAL OF BUON, 2017, 22 (06): : 1447 - 1456
  • [5] Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer
    Cao, Dan
    Guo, Chun-hong
    Liu, Jie-wei
    Yang, Xi
    Li, Qiu
    TUMORI JOURNAL, 2015, 101 (01): : 46 - 51
  • [6] Systemic therapy of metastatic colorectal cancer
    Kubicka, S.
    ONKOLOGE, 2014, 20 (08): : 725 - +
  • [7] Systemic Therapy of Metastatic Colorectal Cancer
    Modest, Dominik Paul
    von Bergwelt, Michael
    ZENTRALBLATT FUR CHIRURGIE, 2019, 144 (03): : 252 - 258
  • [8] Systemic treatment for metastatic colorectal cancer
    Leowattana, Wattana
    Leowattana, Pathomthep
    Leowattana, Tawithep
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (10) : 1569 - 1588
  • [9] Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer
    Neerincx, Maarten
    Poel, Dennis
    Sie, Daoud L. S.
    van Grieken, Nicole C. T.
    Shankaraiah, Ram C.
    van der Wolf-de Lijster, Floor S. W.
    van Waesberghe, Jan-Hein T. M.
    Burggraaf, Jan-Dirk
    Eijk, Paul P.
    Verhoef, Cornelis
    Yistra, Bauke
    Meijer, Gerrit A.
    van de Wiel, Mark A.
    Buffart, Tineke E.
    Verheul, Henk M. W.
    PLOS ONE, 2018, 13 (08):
  • [10] Bevacizumab in elderly patients with metastatic colorectal cancer
    Sclafani, Francesco
    Cunningham, David
    JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) : 78 - 88